Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2006

View Archived Issues

Tanabe Seiyaku updates pipeline status

Angiostatin, endostatin and saxatilin gene cotransfection blocks tumor growth in vivo

Durect reveals intended milestones for 2006

New phase II trial investigates bicifadine for osteoarthritis

Targeting the Sonic hedgehog pathway for CNS pathology in Down's syndrome

Nabi vaccines stimulate antibody responses in phase I trials

Australian centers to study new therapeutics vaccine for genital warts

New inhibitory peptide targets SARS-CoV spike protein to block infectivity

Elan to sell European Prialt rights to Eisai

DOR preparing regulatory submissions for orBec in iGVHD

Ceragenix enters CRADA with CDC to evaluate Ceracide in biofilm prevention

Zonagen seeks stockholder approval to change name to Repros Therapeutics

Igeneon and Celltrion sign letter of intent to amend IGN-311 agreement

ALGRX-4975 completes postsurgery phase II studies

MERLIN study of Ranexa cleared to continue

Genzyme launches test to monitor Gleevec resistance

Results of INFUSE-LR study of Hylenex

NeoPharm updates progress of LEP-ETU

Medivir designates candidate drug from HIV NNRTI program

New potent and selective HCV polymerase inhibitors are effective against multiple genotypes

Ras plays an important tumorgenic role in the liver

Recent GSK patents report new treatments for psychotic disorders

New therapeutics for cancer covered in recent patent literature

Rituxan approved with CHOP for diffuse large B-cell NHL

New data presented on PEDF gene therapy for age-related macular degeneration / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...